Chromogranin A: a novel susceptibility gene for essential hypertension (original) (raw)

References

  1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O’Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y, Subcommittee (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:480–486
    Article PubMed Google Scholar
  2. Gong M, Hubner N (2006) Molecular genetics of human hypertension. Clin Sci (Lond) 110:315–326
    Article CAS Google Scholar
  3. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, Gupta R, Joshi P, Kerkar P, Thanikachalam S, Haridas KK, Jaison TM, Naik S, Maity AK, Yusuf S (2008) Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 371:1435–1442
    Google Scholar
  4. O’Shaughnessy KM (2001) The genetics of essential hypertension. Br J Clin Pharmacol 51:5–11
    Article PubMed Google Scholar
  5. Lifton RP, Gharavi AG, Geller DS (2001) Molecular mechanisms of human hypertension. Cell 104:545–556
    Article CAS PubMed Google Scholar
  6. Kohara K, Tabara Y, Nakura J, Imai Y, Ohkubo T, Hata A, Soma M, Nakayama T, Umemura S, Hirawa N, Ueshima H, Kita Y, Ogihara T, Katsuya T, Takahashi N, Tokunaga K, Miki T (2008) Identification of hypertension-susceptibility genes and pathways by a systemic multiple candidate gene approach: the millennium genome project for hypertension. Hypertens Res 31:203–212
    Article CAS PubMed Google Scholar
  7. Gu D, Su S, Ge D, Chen S, Huang J, Li B, Chen R, Qiang B (2006) Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension 47:1147–1154
    Article CAS PubMed Google Scholar
  8. Pravenec M, Kurtz TW (2007) Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies. Hypertension 49:941–952
    Article CAS PubMed Google Scholar
  9. Yagil Y, Yagil C (2005) The search for the genetic basis of hypertension. Curr Opin Nephrol Hypertens 14:141–147
    Article CAS PubMed Google Scholar
  10. Puddu P, Puddu GM, Cravero E, Ferrari E, Muscari A (2007) The genetic basis of essential hypertension. Acta Cardiol 62:281–293
    Article PubMed Google Scholar
  11. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ (2009) Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 41:348–353
    Article CAS PubMed Google Scholar
  12. Taupenot L, Harper KL, O’Connor DT (2003) The chromogranin–secretogranin family. N Engl J Med 348:1134–1149
    Article CAS PubMed Google Scholar
  13. Winkler H, Fischer-Colbrie R (1992) The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49:497–528
    Article CAS PubMed Google Scholar
  14. Helle KB (1966) Some chemical and physical properties of the soluble protein fraction of bovine adrenal chromaffin granules. Mol Pharmacol 2:298–310
    CAS PubMed Google Scholar
  15. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD (1967) Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215:58–59
    Article CAS PubMed Google Scholar
  16. Iacangelo AL, Eiden LE (1995) Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 58:65–88
    Article CAS PubMed Google Scholar
  17. Aunis D, Metz-Boutigue MH (2000) Chromogranins: current concepts. Structural and functional aspects. Adv Exp Med Biol 482:21–38
    Article CAS PubMed Google Scholar
  18. Huttner WB, Gerdes HH, Rosa P (1991) The granin (chromogranin/secretogranin) family. Trends Biochem Sci 16:27–30
    Article CAS PubMed Google Scholar
  19. Videen JS, Mezger MS, Chang YM, O’Connor DT (1992) Calcium and catecholamine interactions with adrenal chromogranins. Comparison of driving forces in binding and aggregation. J Biol Chem 267:3066–3073
    CAS PubMed Google Scholar
  20. Mahapatra NR, Mahata M, Hazra PP, McDonough PM, O’Connor DT, Mahata SK (2004) A dynamic pool of calcium in catecholamine storage vesicles. Exploration in living cells by a novel vesicle-targeted chromogranin A-aequorin chimeric photoprotein. J Biol Chem 279:51107–51121
    Article CAS PubMed Google Scholar
  21. Mahapatra NR, Taupenot L, Courel M, Mahata SK, O’Connor DT (2008) The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion. Biochemistry 47:7167–7178
    Article CAS PubMed Google Scholar
  22. Kim T, Tao-Cheng JH, Eiden LE, Loh YP (2001) Chromogranin A, an “on/off” switch controlling dense-core secretory granule biogenesis. Cell 106:499–509
    Article CAS PubMed Google Scholar
  23. Courel M, Rodemer C, Nguyen ST, Pance A, Jackson AP, O’Connor DT, Taupenot L (2006) Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem 281:38038–38051
    Article CAS PubMed Google Scholar
  24. Kim T, Zhang CF, Sun Z, Wu H, Loh YP (2005) Chromogranin A deficiency in transgenic mice leads to aberrant chromaffin granule biogenesis. J Neurosci 25:6958–6961
    Article CAS PubMed Google Scholar
  25. Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK (2005) Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942–1952
    Article CAS PubMed Google Scholar
  26. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G (1993) Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405–412
    Article CAS PubMed Google Scholar
  27. Strub JM, Goumon Y, Lugardon K, Capon C, Lopez M, Moniatte M, Van Dorsselaer A, Aunis D, Metz-Boutigue MH (1996) Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173–194 from bovine adrenal medullary chromaffin granules. J Biol Chem 271:28533–28540
    Article CAS PubMed Google Scholar
  28. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324:476–478
    Article CAS PubMed Google Scholar
  29. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ (1997) Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623–1633
    Article CAS PubMed Google Scholar
  30. Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, Chasserot-Golaz S, Helle KB, Aunis D, Metz-Boutigue MH (2005) New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 62:377–385
    Article CAS PubMed Google Scholar
  31. Radek KA, Lopez-Garcia B, Hupe M, Niesman IR, Elias PM, Taupenot L, Mahata SK, O’Connor DT, Gallo RL (2008) The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol 128:1525–1534
    Article CAS PubMed Google Scholar
  32. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A (2002) Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23:967–974
    Article CAS PubMed Google Scholar
  33. Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J, Dickstein K Omland T (2006) Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J 152:927.e1–927.e6
    Google Scholar
  34. Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A, Caidahl K (2009) Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 30:25–32
    Article PubMed Google Scholar
  35. Rao F, Keiser HR, O’Connor DT (2002) Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Ann N Y Acad Sci 971:530–532
    Article CAS PubMed Google Scholar
  36. Chen Y, Rao F, Rodriguez-Flores JL, Mahapatra NR, Mahata M, Wen G, Salem RM, Shih PA, Das M, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, O’Connor DT (2008) Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int 74:115–125
    Article CAS PubMed Google Scholar
  37. Chen Y, Rao F, Rodriguez-Flores JL, Mahata M, Fung MM, Stridsberg M, Vaingankar SM, Wen G, Salem RM, Das M, Cockburn MG, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, Taupenot L, O’Connor DT (2008) Naturally occurring human genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 52:1468–1481
    Article CAS PubMed Google Scholar
  38. Konecki DS, Benedum UM, Gerdes HH, Huttner WB (1987) The primary structure of human chromogranin A and pancreastatin. J Biol Chem 262:17026–17030
    CAS PubMed Google Scholar
  39. Mouland AJ, Bevan S, White JH, Hendy GN (1994) Human chromogranin A gene: molecular cloning, structural analysis, and neuroendocrine cell specific expression. J Biol Chem 269:6918–6926
    CAS PubMed Google Scholar
  40. Wu HJ, Rozansky DJ, Parmer RJ, Gill BM, O’Connor DT (1991) Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. J Biol Chem 266:13130–13134
    CAS PubMed Google Scholar
  41. Helle KB, Corti A, Metz-Boutigue M-H, Tota B (2007) The endocrine role of chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863–2886
    Article CAS PubMed Google Scholar
  42. Takiyyuddin MA, Cervenka JH, Pandian MR, Stuenkel CA, Neumann HP, O’Connor DT (1990) Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab 71:360–369
    Article CAS PubMed Google Scholar
  43. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O’Connor DT (2003) Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058–32067
    Article CAS PubMed Google Scholar
  44. Gaede AH, Lung MS Pilowsky PM (2009) Catestatin attenuates the effects of intrathecal nicotine and isoproterenol. Brain Res. doi:10.1016/j.brainres.2009.09.088
  45. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H (1990) Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 38:845–850
    CAS PubMed Google Scholar
  46. Weiergräber M, Pereverzev A, Vajna R, Henry M, Schramm M, Nastainczyk W, Grabsch H, Schneider T (2000) Immunodetection of alpha1E voltage-gated Ca2+ channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem 48:807–819
    PubMed Google Scholar
  47. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-Boutigue MH, Goumon Y (2006) Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 273:3311–3321
    Article CAS PubMed Google Scholar
  48. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 28:1117–1127
    Article CAS PubMed Google Scholar
  49. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275:10745–10753
    Article CAS PubMed Google Scholar
  50. Zhang D, Lavaux T, Sapin R, Lavigne T, Castelain V, Aunis D, Metz-Boutigue MH, Schneider F (2009) Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med 41:38–44
    Article CAS PubMed Google Scholar
  51. Dimsdale JE, O’Connor DT, Ziegler M, Mills P (1992) Chromogranin A correlates with norepinephrine release rate. Life Sci 51:519–525
    Article CAS PubMed Google Scholar
  52. Bernini G, Moretti A, Salvetti A (2002) Chromogranin A in normal subjects, essential hypertensive and adrenalectomized patients. Clin Endocrinol 57:41–50
    Article Google Scholar
  53. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O’Connor DT (1991) Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 70:33–45
    CAS Google Scholar
  54. O’Connor DT (1985) Plasma chromogranin A. Initial studies in human hypertension. Hypertension 7:176–179
    Google Scholar
  55. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Parmer RJ, Barbosa JA, O’Connor DT (1990) Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81:185–195
    CAS PubMed Google Scholar
  56. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, O’Connor DT (1995) Chromogranin A in human hypertension. Influence of heredity. Hypertension 26:213–220
    CAS PubMed Google Scholar
  57. Schober M, Howe PR, Sperk G, Fischer-Colbrie R, Winkler H (1989) An increased pool of secretory hormones and peptides in adrenal medulla of stroke-prone spontaneously hypertensive rats. Hypertension 13:469–474
    CAS PubMed Google Scholar
  58. O’Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK, Wu H, Kennedy BP, Ziegler MG, Wright FA, Schlager G, Parmer RJ (1999) Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press 8:285–295
    Article PubMed Google Scholar
  59. Fries RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-Schoenbein GW, O’Connor DT (2004) Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems. Hypertension 43:1301–1311
    Article CAS PubMed Google Scholar
  60. Corti A, Gasparri A, Chen FX, Pelagi M, Brandazza A, Sidoli A, Siccardi AG (1996) Characterisation of circulating chromogranin A in human cancer patients. Br J Cancer 73:924–932
    CAS PubMed Google Scholar
  61. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O’Connor DT, Hamilton BA (2004) Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 74:197–207
    Article CAS PubMed Google Scholar
  62. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O’Connor DT (2007) Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115:2271–2281
    Article CAS PubMed Google Scholar
  63. Comings DE, MacMurray JP (2000) Molecular heterosis: a review. Mol Genet Metab 71:19–31
    Article CAS PubMed Google Scholar
  64. Takiyyuddin MA, Cervenka JH, Hsiao RJ, Barbosa JA, Parmer RJ, O’Connor DT (1990) Chromogranin A. Storage and release in hypertension. Hypertension 15:237–246
    CAS PubMed Google Scholar
  65. Montero-Hadjadje M, Vaingankar S, Elias S, Tostivint H, Mahata SK, Anouar Y (2008) Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) 192:309–324
    CAS Google Scholar
  66. Helle KB (2009) The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res(PMID: 19640932) (in press)
  67. Aardal S, Helle KB (1992) The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 41:9–18
    Article CAS PubMed Google Scholar
  68. Angeletti RH, Aardal S, Serck-Hanssen G, Gee P, Helle KB (1994) Vasoinhibitory activity of the synthetic peptides from the amino terminus of the adrenomedullary chromogranin A. Acta Physiol Scand 152:11–19
    Article CAS PubMed Google Scholar
  69. Brekke JF, Osol GJ, Helle KB (2002) N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. Regul Pept 105:93–100
    Article CAS PubMed Google Scholar
  70. Brekke JF, Kirkeleit J, Lugardon K, Helle KB (2000) Vasostatins: dilators of bovine resistance arteries. Adv Exp Med Biol 482:239–246
    Article CAS PubMed Google Scholar
  71. Russell J, Gee P, Liu SM, Angeletti RH (1994) Stimulation of parathyroid hormone secretion by low calcium is inhibited by amino terminal chromogranin peptides. Endocrinology 135:337–342
    Article CAS PubMed Google Scholar
  72. Helle KB (2004) The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev 79:769–794
    Article PubMed Google Scholar
  73. Blois A, Srebro B, Mandalà M, Corti A, Helle KB, Serck-Hanssen G (2006) The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept 135:78–84
    Article CAS PubMed Google Scholar
  74. Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME, Corti A (2004) Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J 18:554–556
    CAS PubMed Google Scholar
  75. Watson T, Goon PK, Lip GY (2008) Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal 10:1079–1088
    Article CAS PubMed Google Scholar
  76. Landmesser U, Drexler H (2005) The clinical significance of endothelial dysfunction. Curr Opin Cardiol 20:547–551
    Article PubMed Google Scholar
  77. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G (2001) Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191–196
    CAS PubMed Google Scholar
  78. Tota B, Mazza R, Angelone T, Nullans G, Metz-Boutigue MH, Aunis D, Helle KB (2003) Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul Pept 114:123–130
    Article CAS PubMed Google Scholar
  79. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B (2004) Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol 139:20–28
    Article CAS PubMed Google Scholar
  80. Corti A, Mannarino C, Mazza R, Colombo B, Longhi R, Tota B (2002) Vasostatins exert negative inotropism in the working heart of the frog. Ann N Y Acad Sci 971:362–365
    Article CAS PubMed Google Scholar
  81. Tota B, Angelone T, Mazza R, Cerra MC (2008) The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr Med Chem 15:1444–1451
    Article CAS PubMed Google Scholar
  82. Cerra MC, Gallo MP, Angelone T, Quintieri AM, Pulerà E, Filice E, Guérold B, Shooshtarizadeh P, Levi R, Ramella R, Brero A, Boero O, Metz-Boutigue MH, Tota B, Alloatti G (2008) The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J 22:3992–4004
    Article CAS PubMed Google Scholar
  83. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B (2006) Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 101:43–52
    Article CAS PubMed Google Scholar
  84. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF (2006) Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111:508–531
    CAS PubMed Google Scholar
  85. Gallo MP, Levi R, Ramella R, Brero A, Boero O, Tota B, Alloatti G (2007) Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 292:H2906–H2912
    Article CAS PubMed Google Scholar
  86. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano G, Cerra MC (2007) Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am J Physiol Heart Circ Physiol 293:H719–H727
    Article CAS PubMed Google Scholar
  87. Mahapatra NR (2008) Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 80:330–338
    Article CAS PubMed Google Scholar
  88. O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ (2002) Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335–1345
    Article PubMed Google Scholar
  89. Mahata SK, Mahata M, Wakade AR, O’Connor DT (2000) Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344–364)): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525–1535
    Article CAS PubMed Google Scholar
  90. Mahapatra NR, Mahata M, Mahata SK, O’Connor DT (2006) The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens 24:895–904
    Article CAS PubMed Google Scholar
  91. Herrero CJ, Alés E, Pintado AJ, López MG, García-Palomero E, Mahata SK, O’Connor DT, García AG, Montiel C (2002) Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis. J Neurosci 22:377–388
    CAS PubMed Google Scholar
  92. Ferrier C, Cox H, Esler M (1993) Elevated total body noradrenaline spillover in normotensive members of hypertensive families. Clin Sci (Lond) 84:225–230
    CAS Google Scholar
  93. Kennedy BP, Mahata SK, O’Connor DT, Ziegler MG (1998) Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19:1241–1248
    Article CAS PubMed Google Scholar
  94. Mazza R, Gattuso A, Mannarino C, Brar BK, Barbieri SF, Tota B, Mahata SK (2008) Catestatin (chromogranin A344–364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 295:H113–H122
    Article CAS PubMed Google Scholar
  95. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC (2008) The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149:4780–4793
    Article PubMed Google Scholar
  96. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de Barry J, Chasserot-Golaz S, Delalande F, Van Dorsselaer A, Schneider F, Helle KB, Aunis D, Prévost G, Metz-Boutigue MH (2009) Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS One 4:e4501
    Article PubMed CAS Google Scholar
  97. Salem RM, Cadman PE, Chen Y, Rao F, Wen G, Hamilton BA, Rana BK, Smith DW, Stridsberg M, Ward HJ, Mahata M, Mahata SK, Bowden DW, Hicks PJ, Freedman BI, Schork NJ, O’Connor DT (2008) Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 19:600–614
    Article CAS PubMed Google Scholar

Download references